James E. G. Charlesworth

James E. G. Charlesworth

Auto-generated profile, based on publicly available information

James E. G. Charlesworth

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2017 in Journal of Evidence-Based Medicine
Verified
Journal Article
Closed access
PDF file
JCJames E.G. Charlesworth
James E.G. Charlesworth
GPGrace Petkovic
Grace Petkovic
JKJohn M. Kelley
John M. Kelley
MHMonika Hunter
Monika Hunter
IOIgho Onakpoya
Igho Onakpoya
JHJeremy Howick
Jeremy Howick

19 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MNMichael T. H. Ng
Michael T. H. Ng
RBRowie Borst
Rowie Borst
HGHamez Gacaferi
Hamez Gacaferi
SDSarah Davidson
Sarah Davidson
JAJessica E. Ackerman
Jessica E. Ackerman
SDStephanie G. Dakin
Stephanie G. Dakin
Frozen shoulder is a spontaneously self-resolving chronic inflammatory fibrotic human disease, which distinguishes the condition from most fibrotic diseases that are progressive and irreversible. Using single-cell analysis, we identify pro-inflammatory MERTKlowCD48+ macrophages and MERTK + LYVE1 + MRC1+ macrophages enriched for negative regulators of inflammation which co-exist in frozen shoulder capsule tissues. Micro-cultures of patient-derived cells identify integrin-mediated cell-matrix interactions between MERTK+ macrophages and pro-resolving DKK3+ and POSTN+ fibroblasts, suggesting that matrix remodelling plays a role in frozen shoulder resolution. Cross-tissue analysis reveals a shared gene expression cassette between shoulder capsule MERTK+ macrophages and a respective population enriched in synovial tissues of rheumatoid arthritis patients in disease remission, supporting the concept that MERTK+ macrophages mediate resolution of inflammation and fibrosis. Single-cell transcriptomic profiling and spatial analysis of human foetal shoulder tissues identify MERTK + LYVE1 + MRC1+ macrophages and DKK3+ and POSTN+ fibroblast populations analogous to those in frozen shoulder, suggesting that the template to resolve fibrosis is established during shoulder development. Crosstalk between MerTK+ macrophages and pro-resolving DKK3+ and POSTN+ fibroblasts could facilitate resolution of frozen shoulder, providing a basis for potential therapeutic resolution of persistent fibrotic diseases.

15 August 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
EREwan A Ross
Ewan A Ross
RCRuth E Coughlan
Ruth E Coughlan
AFAdriana Flores-Langarica
Adriana Flores-Langarica
SBSaeeda Bobat
Saeeda Bobat
JMJennifer L. Marshall
Jennifer L. Marshall
ACAdam F. Cunningham
Adam F. Cunningham
Hematopoietic cells constitutively express CD31/PECAM1, a signaling adhesion receptor associated with controlling responses to inflammatory stimuli. Although expressed on CD4+ T cells, its function on these cells is unclear. To address this, we have used a model of systemic Salmonella infection that induces high levels of T cell activation and depends on CD4+ T cells for resolution. Infection of CD31-deficient (CD31KO) mice demonstrates that these mice fail to control infection effectively. During infection, CD31KO mice have diminished numbers of total CD4+ T cells and IFN-γ–secreting Th1 cells. This is despite a higher proportion of CD31KO CD4+ T cells exhibiting an activated phenotype and an undiminished capacity to prime normally and polarize to Th1. Reduced numbers of T cells reflected the increased propensity of naive and activated CD31KO T cells to undergo apoptosis postinfection compared with wild-type T cells. Using adoptive transfer experiments, we show that loss of CD31 on CD4+ T cells alone is sufficient to account for the defective CD31KO T cell accumulation. These data are consistent with CD31 helping to control T cell activation, because in its absence, T cells have a greater propensity to become activated, resulting in increased susceptibility to become apoptotic. The impact of CD31 loss on T cell homeostasis becomes most pronounced during severe, inflammatory, and immunological stresses such as those caused by systemic Salmonella infection. This identifies a novel role for CD31 in regulating CD4 T cell homeostasis.

21 June 2023 in European Journal of Haematology
Verified
Journal Article
Closed access
JCJames E. G. Charlesworth
James E. G. Charlesworth
AKAkhila Kavirayani
Akhila Kavirayani

11 June 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
JCJames E.G. Charlesworth
James E.G. Charlesworth
SWShaun Wilson
Shaun Wilson
AQAmrana Qureshi
Amrana Qureshi
EBEsther Blanco
Esther Blanco
AMAmy Mitchell
Amy Mitchell
AKAkhila Kavirayani
Akhila Kavirayani

26 November 2015 in BMJ Open
Verified
Journal Article
Open access
PDF file
GPGrace Petkovic
Grace Petkovic
JCJames E G Charlesworth
James E G Charlesworth
JKJohn Kelley
John Kelley
FMFranklin Miller
Franklin Miller
NRNia Roberts
Nia Roberts
JHJeremy Howick
Jeremy Howick
Introduction Placebos have long provided a robust control for evaluating active pharmacological preparations, but frequently demonstrate a variable therapeutic effect when delivered in double-blinded placebo-controlled trials. Delivery of placebos as treatment alone has been considered unethical, as it has been thought that deception is essential for their effect. However, recent evidence suggests that clinical benefit can be derived from placebos delivered without deception (unblinded/open-label) manner. Here, we present a protocol for the first systematic review and meta-analysis of studies of the effects of non-deceptive placebos compared with no treatment. Methods and analysis This protocol will compare the effect of placebos delivered non-deceptively to no treatment. It will also assess the methods of delivery used for non-deceptive placebos. Studies will be sought through relevant database searches and will include those within disease settings and those among healthy controls. To be included, trials must include both non-deceptive (open-label) placebo and no treatment groups. All data extraction and analysis will be conducted by two independent reviewers. The analysis will evaluate any differences in outcome measures between the non-deceptive placebo and no treatment groups. Outcome measures will be the clinically-relevant outcomes detailed in the primary papers. The delivery methods, such as verbal instructions, which may provide positive expectations and outcomes, of non-deceptive placebos will also be assessed. Each study will be comprehensively assessed for bias. Subgroup analyses will identify any discrepancies among heterogeneous data. Ethics and dissemination This review does not require ethical approval. The completed review will be widely disseminated by publication and social media where appropriate. This protocol has been registered on PROSPERO (2015:CRD42015023347).